Yellow Fever

An acute infectious disease primarily of the tropics, caused by a virus and transmitted to man by mosquitoes of the genera Aedes and Haemagogus. The severe form is characterized by fever, HEMOLYTIC JAUNDICE, and renal damage.

Also Known As:

Networked: 1791 relevant articles (66 outcomes, 161 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Japanese Encephalitis
2.	Dengue (Dengue Fever)
3.	Infections
4.	Measles
5.	Tick-Borne Encephalitis (Encephalitis, Tick Borne)

Experts

1.	Monath, Thomas P: 35 articles (01/2022 - 01/2002)
2.	Galler, Ricardo: 24 articles (04/2015 - 01/2002)
3.	Guirakhoo, Farshad: 20 articles (02/2011 - 01/2002)
4.	Piermarini, Peter M: 19 articles (03/2022 - 04/2009)
5.	Barrett, Alan D T: 15 articles (01/2022 - 07/2002)
6.	Monath, T P: 14 articles (12/2006 - 02/2000)
7.	Homma, Akira: 13 articles (01/2021 - 09/2006)
8.	Niedrig, Matthias: 13 articles (09/2020 - 11/2004)
9.	Freire, Marcos S: 13 articles (01/2018 - 01/2002)
10.	Martins-Filho, Olindo Assis: 12 articles (01/2021 - 01/2010)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Yellow Fever:

1.	VaccinesIBA 01/01/2018 - "The highly efficacious live-attenuated 17D yellow fever (YF) vaccine is occasionally associated with rare life-threatening adverse events. " 08/11/2011 - "Live, attenuated yellow fever (YF) 17D vaccine is highly efficacious but causes rare, serious adverse events resulting from active replication in the host and direct viral injury to vital organs. " 05/10/1999 - "Yellow fever (YF) 17D vaccine virus, having a 60-year history of safe and effective use, is an ideal vector to deliver heterologous genes from other medically important flaviviruses. " 03/15/2012 - "Effective vaccines against yellow fever have been available for almost 70 years and are responsible for a significant reduction of occurrences of the disease worldwide; however, approximately 200,000 cases of yellow fever still occur annually, principally in Africa. " 01/01/2021 - "Vaccine entry requirements have proved effective in controlling the international spread of yellow fever but more can be done to ensure better use of this measure. "
2.	Dengue VaccinesIBA 11/01/2012 - "Chimeric yellow fever 17D/DENV-1-4 viruses (CYD-1-4) have been developed as a tetravalent dengue vaccine candidate which is currently being evaluated in efficacy trials in Asia and America. " 09/07/2012 - "Immunogenicity and safety of tetravalent dengue vaccine in 2-11 year-olds previously vaccinated against yellow fever: randomized, controlled, phase II study in Piura, Peru." 12/01/2021 - "Currently, Dengvaxia, a live-attenuated chimeric yellow-fever/tetravalent dengue vaccine (CYD-TDV) developed by Sanofi Pasteur, has been licensed and approved for clinical use in some countries. " 12/01/2021 - " covered: This article discusses recent dengue vaccine developments based on the published literature and ClinicalTrials.gov website up to December 2020.Expert opinion: The first live-attenuated chimeric yellow-fever/tetravalent dengue vaccine (CYD-TDV), Dengvaxia, has been licensed in several countries. " 01/01/2018 - "Safety issues from a Phase 3 clinical trial of a live-attenuated chimeric yellow fever tetravalent dengue vaccine."
3.	Proteins (Proteins, Gene)FDA Link 12/01/1986 - "Protection against yellow fever in monkeys by immunization with yellow fever virus nonstructural protein NS1." 09/26/2018 - "In this study, we describe the initial development of a chimeric virus containing the prM/E proteins of a ZIKV epidemic strain incorporated into a yellow fever 17-D attenuated backbone. " 12/01/2021 - "In the yellow fever mosquito, Aedes aegypti, a number of aaNATs and aaNAT-like proteins have been reported. " 06/01/2019 - "Development and Clinical Evaluation of a Rapid Diagnostic Test for Yellow Fever Non-Structural Protein 1." 01/01/2019 - "Structure of the yellow fever NS5 protein reveals conserved drug targets shared among flaviviruses."
4.	Attenuated VaccinesIBA 10/05/2017 - "To test this possibility, we used the yellow fever live-attenuated vaccine (YFLAV) as a model to study the molecular correlates of reactogenicity or adverse events (AEs). " 10/26/2023 - "At least 10% of patients in our cohort needed a live attenuated vaccine for either MMR or yellow fever. " 10/26/2022 - "The yellow fever (YF) live attenuated vaccine strain 17D (termed 17D) has been widely used for the prevention and control of YF disease. " 10/26/2022 - "Development of a Bicistronic Yellow Fever Live Attenuated Vaccine with Reduced Neurovirulence and Viscerotropism." 09/01/2021 - "The disease yellow fever (YF) is prevented by a live-attenuated vaccine, termed 17D, which has been in use since the 1930s. "
5.	Neutralizing AntibodiesIBA 10/01/2019 - "In this review, we address the causes of the recent yellow fever outbreaks, why fractional dose yellow fever vaccination works, the role of virus neutralizing antibodies in the protection against yellow fever, and the need for revaccination. " 12/29/2021 - "In the original trial, the neutralizing antibody response was measured in older travelers (aged 60-81 years, N = 28) and young adults (aged 18-28 years, N = 30) up to 28 days after a primary yellow fever vaccination. " 10/27/2017 - "The primary endpoint of the study was the percentage of infants with protective immunity against yellow fever, measured by the titer of neutralizing antibodies in a venous blood sample. " 11/01/2023 - "Standardization, validation, and comparative evaluation of a faster and high-performance test for quantification of yellow fever neutralizing antibodies." 10/01/2019 - "The need for the presence of virus neutralizing antibodies (VNA) to protect an individual against yellow fever depends on the epidemiological setting. "
6.	Combined VaccinesIBA 05/01/2004 - "Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates." 01/01/2015 - "The candidate currently at the most advanced clinical development stage, a live-attenuated tetravalent vaccine based on the chimeric yellow fever-dengue virus (CYD-TDV), has progressed to Phase 3 efficacy studies. " 01/01/2014 - "A live-attenuated tetravalent vaccine based on chimeric yellow fever-dengue virus (CYD-TDV) has progressed to phase III efficacy studies. " 01/01/2014 - "The candidate currently at the most advanced clinical development stage, a live-attenuated tetravalent vaccine based on chimeric yellow fever dengue virus, has progressed to phase III efficacy studies. " 01/01/2019 - "With increasing incidence of yellow fever, mass campaign vaccinations are underway and little ophthalmological alterations have been reported in literature, specially regarding non-combined vaccines. "
7.	Yellow Fever Vaccine (Vaccine, Yellow Fever)FDA Link 12/04/2018 - "Persons receiving a fractional dose of yellow fever vaccine do not require a booster vaccination for long-term protection against yellow fever. " 01/01/2023 - "Considering that vaccination with yellow fever vaccine (YFV) is the most important method to prevent and control yellow fever (YF), this study synthesized evidence on factors associated with YFV failure. " 01/01/2023 - "Evidence indicates that fractional doses of yellow fever vaccine are safe and sufficiently immunogenic for use during yellow fever outbreaks. " 01/01/2023 - "We describe 5 cases of yellow fever vaccine-associated viscerotropic disease (YEL-AVD) in 2 familial clusters during the 2017-2018 yellow fever (YF) vaccination campaign in São Paulo state, Brazil. " 12/31/2022 - "Despite the existence of a highly efficient yellow fever vaccine, yellow fever reemergence throughout Africa and the Americas has put 900 million people in 47 countries at risk of contracting the disease. "
8.	AntigensIBA 05/01/2001 - "The resulting chimeric virus contains the antigens responsible for protection against West Nile but retains the replication efficiency of yellow fever 17D. " 01/01/2014 - "Interestingly, we found that the peak of the yellow fever-specific CD8 T cell response was determined by the rate of T cell proliferation and not by the precursor frequency of antigen-specific cells as has been suggested in several studies in mice. " 11/29/2010 - "CD8+ gamma-delta TCR+ and CD4+ T cells produce IFN-γ at 5-7 days after yellow fever vaccination in Indian rhesus macaques, before the induction of classical antigen-specific T cell responses." 07/01/2004 - "We investigated whether the cost of an immune response in the yellow fever mosquito, Aedes aegypti, is modulated by the antigen that activates the melanization immune response. " 11/01/2003 - "Cells within those tissues stained positively with a polyclonal antibody against YFV antigens (1:1,600 dilution), and yellow fever was diagnosed for the first time in the brown howler in the area."
9.	ChimeriVaxIBA 06/20/2002 - "Chimeric yellow fever (YF)-dengue (DEN) viruses (ChimeriVax-DEN) were reconstructed to correct amino acid substitutions within the envelope genes of original constructs described by Guirakhoo et al. (2001, J. " 05/01/2001 - "ChimeriVax vaccines utilize the safe and effective vaccine against the prototype flavivirus -yellow fever 17D- as a live vector. " 09/01/2005 - "In this study, we compare the neurovirulence of ChimeriVax vaccine candidates in suckling mice inoculated by the intracerebral (IC) route with graded doses of the test article or yellow fever 17D vaccine as a reference control. " 01/01/2018 - "Chimeric yellow fever 17D-Zika virus (ChimeriVax-Zika) as a live-attenuated Zika virus vaccine." 01/01/2017 - "The most clinically advanced dengue vaccine is the chimeric yellow fever-dengue vaccine (CYD) that employs the yellow fever virus 17D strain as the replication backbone (Chimerivax-DEN; CYD-TDV). "
10.	SofosbuvirIBA 11/25/2019 - "Efficacy of sofosbuvir as treatment for yellow fever: protocol for a randomised controlled trial in Brazil (SOFFA study)." 01/01/2019 - "Sofosbuvir use for yellow fever: a new perspective treatment." 01/01/2020 - "In the most recent Brazilian yellow fever (YF) outbreak, a group of clinicians and researchers initiated in mid-January 2018 a considerable effort to develop a multicenter randomized controlled clinical trial to evaluate the effect of sofosbuvir on YF viremia and clinical outcomes (Brazilian Clinical Trials Registry: RBR-93dp9n). " 11/01/2019 - "Moreover, after an off-label treatment with sofosbuvir, the two female patients diagnosed with yellow fever infection displayed a reduction in blood viremia and an improvement in the course of the disease, which was observed in the laboratory medical parameters related to disease evolution. " 01/01/2019 - "Key-words: Yellow fever virus; Yellow fever, antiviral; sofosbuvir."

Therapies and Procedures

1.	Therapeutics 10/01/2022 - "However, there is no curative therapy for yellow fever. " 01/01/2020 - "Vaccination and Therapeutics: Responding to the Changing Epidemiology of Yellow Fever." 01/01/2020 - "Vaccination and Therapeutics: Responding to the Changing Epidemiology of Yellow Fever." 01/01/2004 - ""Venerate the Lancet": Benjamin Rush's yellow fever therapy in context." 12/01/1999 - "A better knowledge of the complex interactions between the virus and the host is requested before initiating new actions in prophylaxy and therapy against yellow fever."
2.	Wearable Electronic Devices 01/01/2017 - "Efficacy of Some Wearable Devices Compared with Spray-On Insect Repellents for the Yellow Fever Mosquito, Aedes aegypti (L.) (Diptera: Culicidae)." 01/01/2017 - "Erratum: Efficacy of Some Wearable Devices Compared with Spray-On Insect Repellents for the Yellow Fever Mosquito, Aedes aegypti (L.) (Diptera: Culicidae)."
3.	Injections 08/01/1986 - "We compared the immune responses of Senegalese children to the separate or simultaneous injections of yellow fever and hepatitis B vaccines. " 10/31/1920 - "Injections into guinea pigs of the blood and the emulsions of liver and kidney obtained at autopsy from a fatal case of yellow fever in Merida induced in some of these animals, after a period of several days incubation, a rise of temperature which lasted 1, 2, or more days. " 03/01/2003 - "In a randomized study, 48 healthy volunteers either were immunized against yellow fever, polio, diphtheria, and tetanus (the group receiving intervention with nonchlamydial antigen) or received saline injections (the placebo group). " 04/01/2001 - "Acute disseminated encephalomyelitis (ADEM), a monophasic and multifocal illness of the white and grey matter, has been observed following various viral or bacterial infections as well as vaccine injections for diseases such as pertussis, tetanus and yellow fever. " 04/01/2015 - "The recent changes concern the schedule of injections: primovaccination DTCaPolio of children and boosters for adults, accelerated schedule of Japanese encephalitis and hepatitis B immunization, preexposure rabies immunization and vaccination against yellow fever; and the indications of poliomyelitis vaccine, immunization of children against Japanese encephalitis and conjugated vaccines against meningococcal meningitis."
4.	Contraindications 01/01/2020 - "Travel health practitioners should do individualised assessments of the risks and benefits of yellow fever vaccination to identify potential contraindications. " 01/01/2023 - "HIV-positive participants aged 18-59 years, with baseline CD4+ T-cell count of at least 200 cells per mL, and who were not pregnant, had no previous history of yellow fever vaccination or infection, and had no contraindication for yellow fever vaccination were recruited from the community. " 01/01/2023 - "Eligible children were aged 9-59 months without contraindications for vaccination, without history of previous yellow fever vaccination or infection and not requiring yellow fever vaccination for travelling. " 01/01/2021 - "Eligible participants were aged 18-59 years, had no contraindications for vaccination, were not pregnant or lactating, had no history of yellow fever vaccination or infection, and did not require yellow fever vaccination for travel. " 10/01/2011 - "This serological study was able to show a persistent protective antibody titer, after a previous vaccination, even going back 60 years, allowing patients to travel in a yellow-fever endemic area despite a contraindication, and without requiring any vaccine booster."
5.	Hormone Replacement Therapy (Therapy, Hormone Replacement) 07/04/2008 - "The genesis of these differences is uncertain but not entirely related to gonadal hormones (differences are seen in pre-pubertal and post-menopausal subjects not on hormone replacement therapy) or female sex (males had greater serological response for pneumococcal, diphtheria, yellow fever, Venezuelan equine encephalitis and in some studies with rabies vaccine. "